Physician profile
Suja Sadasivan
NPI 1881822021
$65,285.31
in general payments reported to CMS, 2019-2025
44 companies · $19K in 2025
The $19K reported for 2025 was more than what 93% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,779 · 2020: $13K · 2021: $14K · 2022: $9,536 · 2023: $5,123 · 2024: $1,603 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $14K · Food and Beverage: $4,550 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,938 · Education: $1,686 · Travel and Lodging: $1,645.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $14,332.50 |
| Food and Beverage | $4,550.11 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,937.50 |
| Education | $1,686.03 |
| Travel and Lodging | $1,644.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $17,283.00 | 2019-2025 | Crexont, Ongentys, Rytary |
| Abbvie INC. | $14,768.93 | 2019-2025 | Ubrelvy, Qulipta, Botox |
| Allergan, INC. | $13,044.33 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $6,071.35 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $5,420.37 | 2021 | |
| Boston Scientific Corporation | $1,746.05 | 2025 | Vercise, General - Dbs |
| Mdd US Operations, LLC | $1,084.80 | 2019-2025 | Gocovri, Apokyn, Apokyn |
| Pfizer INC. | $693.06 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $684.33 | 2019-2025 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $671.36 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Neurocrine Biosciences, INC. | $466.28 | 2019-2022 | |
| Amgen INC. | $437.92 | 2019-2023 | Aimovig |
| Acorda Therapeutics, INC | $274.38 | 2019-2023 | Inbrija |
| Medtronic USA, INC. | $253.20 | 2019 | |
| Merz Pharmaceuticals, LLC | $243.22 | 2022-2025 | Xeomin |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suja Sadasivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.